🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Red Deer
Clinical trial register · Canada

Clinical Trials in Red Deer, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 2809 Montreal 1902 Vancouver 1179 Calgary 1061 Edmonton 1017
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer6 University of Calgary4 Ipsen3 Merz Therapeutics GmbH2 Sanofi2
Site location
Toronto2809 Montreal1902 Vancouver1179 Calgary1061 Edmonton1017
All 255 locations
Target enrolment
to

Trials with a site in Red Deer

34 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
Machine Learning and Artificial Intelligence Algorithms to Optimize the Performance and Delivery of Acute Dialysis
NCT07312929Renal Dialysis, Renal Replacement Therapy, Renal Diseases, Quality Health Care
University of Alberta
Observational
7,500
Calgary, Edmonton, Fort McMurray, Grand Prairie, Lethbridge, Medicine Hat, Red Deer, St. Albert
2026-10-01
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Calgary, Edmonton, Red Deer, Kelowna, Sydney, Sarnia, Stouffville, Toronto
2026-08-24
Active, closed
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
NCT07265479Atopic Dermatitis
DrugTapinarof
Organon and Co
Phase 3
187
Calgary, Red Deer, Surrey, Winnipeg, Halifax, Burlington, Hamilton, Niagara Falls
2025-12-29
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Barrie, Calgary, Fredericton, London, Québec, Red Deer, Surrey
2025-11-14
Active, closed
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390Hidradenitis Suppurativa
DrugRitlecitinib
Pfizer
Phase 2
128
Calgary, Edmonton, Red Deer, Newmarket, Ottawa, Toronto, Québec
2025-11-13
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Edmonton, Red Deer, Mississauga, Niagara Falls, Ottawa, Québec
2025-10-30
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Kelowna, Lévis, Oakville, Québec, Red Deer, Toronto
2025-09-30
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700Episodic Migraine
DrugXeomin
Merz Therapeutics GmbH
Phase 3
990
Montreal, Red Deer
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713Chronic Migraine
DrugXeomin
Merz Therapeutics GmbH
Phase 3
780
Montreal, Red Deer
2025-08-21
Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308Alopecia Areata
DrugDeuruxolitinib
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Calgary, Edmonton, Red Deer, Kelowna, Surrey, Markham, Newmarket, Toronto
2025-08-05
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Calgary, Red Deer, Kelowna, New Westminster, North Vancouver, Penticton, Surrey, Moncton
2025-07-22
Active, closed
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
NCT07118891Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
AbCellera Biologics Inc.
Phase 1/2
136
Calgary, Red Deer, Vancouver, Toronto, Lévis, Montreal, Mount Royal, Québec
2025-06-23
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Red Deer, Richmond, Vancouver, Victoria, Bridgewater, Halifax, Sydney, Brampton
2025-06-04
Recruiting
Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)
NCT07024329Cancer
University of Calgary
Not applicable
1,055
Calgary, Edmonton, High River, Red Deer
2025-05-16
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 3
674
Calgary, Red Deer, Winnipeg, Barrie, Guelph, London, Markham, Newmarket
2025-04-01
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Red Deer, Kelowna, Surrey, Halifax, Brampton, Sarnia, Lévis
2025-03-11
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Edmonton, Red Deer, Surrey, Ajax, Barrie, Coburg, Guelph, Hamilton
2025-01-08
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Edmonton, Red Deer, London
2024-11-15
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
DrugCorabotase
Ipsen
Phase 2
670
Calgary, Lévis, Québec, Red Deer, Sarnia
2024-10-10
Recruiting
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
NCT06320431Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
DrugTenecteplase
University of Calgary
Phase 3
4,000
Calgary, Medicine Hat, Red Deer, Edmonton, Kelowna, New Westminster, Vancouver, Brandon
2024-09-26
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
2,099
Calgary, Edmonton, Red Deer, Surrey, Winnipeg, St. John's, Ajax, Barrie
2024-09-04
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Calgary, Edmonton, Red Deer, Vancouver, Moncton, St. John's, Hamilton, London
2024-05-20
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Calgary, Edmonton, Red Deer, Kelowna, Surrey, Winnipeg, Ajax, London
2024-05-08
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
394
Calgary, Red Deer, Markham, Mississauga, Toronto, Québec
2024-01-19
Active, closed
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444Chronic Migraine
DrugBotulinum toxin type A
Ipsen
Phase 3
759
Halifax, Montreal, Red Deer, Sarnia, Victoria
2023-10-12
Active, closed
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457Episodic Migraine
DrugBotulinum toxin type A
Ipsen
Phase 3
751
Montreal, Red Deer, Sarnia
2023-09-29
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Calgary, Edmonton, Red Deer, Surrey, Winnipeg, St. John's, Hamilton, London
2023-06-21
Recruiting
Alberta Collaborative QI Strategies to Improve Outcomes of Moderate and Late Preterm Infants (ABC-QI Trial)
NCT05231200Length of Stay
University of Calgary
Not applicable
9,500
Calgary, Edmonton, Lethbridge, Medicine Hat, Red Deer
2023-05-01
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Calgary, Edmonton, Red Deer, Kelowna, Vancouver, Moncton, Halifax, New Minas
2023-03-09
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Calgary, Edmonton, Red Deer, Surrey, Winnipeg, Ajax, Barrie, Hamilton
2022-08-22
Recruiting
Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04096430Autism Spectrum Disorder, Neurodevelopmental Disorders, Cerebral Palsy
University of Alberta
Not applicable
96
Calgary, Camrose, Edmonton, Grande Prairie, Red Deer
2022-03-01
Active, closed
Identification and Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning Pathway
NCT04744298Acute Respiratory Distress Syndrome, Hypoxemic Respiratory Failure, ARDS, Human
University of Calgary
Not applicable
19,916
Calgary, Edmonton, Fort McMurray, Grande Prairie, Lethbridge, Medicine Hat, Red Deer, St. Albert
2021-04-01
Active, closed
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
NCT04636697SARS-CoV-2 Infection
Medicago
Phase 2/3
30,918
Red Deer, Halifax, Brampton, Guelph, Newmarket, Toronto, Lévis, Mirabel
2020-11-19
Active, closed
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479Alopecia Areata
Sun Pharmaceutical Industries, Inc.
Phase 2/3
1,000
Calgary, Red Deer, Kelowna, Surrey, Winnipeg, Barrie, Etobicoke, Guelph
2019-04-04
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-canada/city/red-deer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Red Deer.

How many clinical trials are recruiting in Red Deer?

16 of the 34 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 1 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Red Deer), 34 studies
PhaseStudiesRecruitingShare
Phase 3221264.7%
Not applicable4311.8%
Phase 2318.8%
Phase 2/3308.8%
Observational102.9%
Phase 1/2102.9%

Most active sponsors

Lead sponsors with the most studies (Red Deer)
Lead sponsorStudiesRecruiting
Pfizer63
University of Calgary43
Ipsen30
Merz Therapeutics GmbH22
Sanofi20
Sun Pharmaceutical Industries, Inc.21
University of Alberta21
AbbVie10
AbCellera Biologics Inc.10
Alumis Inc10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.